1000025-92-2

Basic information

• Product Name: 3,5-bis-benzyloxy-pyridine-2-carbonitrile
• Synonyms: 3,5-bis-benzyloxy-pyridine-2-carbonitrile;3,5-Bis(phenylmethoxy)-2-pyridinecarbonitrile;3,5-Bis(benzyloxy)picolinonitrile;3,5-bis(phenylmethoxy)pyridine-2-carbonitrile
• CAS NO: 1000025-92-2
• Molecular Formula: C₂₀H₁₆N₂O₂
• Molecular Weight: 316
• Mol File: 1000025-92-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 535.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.23
• PKA: -5.06±0.10(Predicted)
• CAS DataBase Reference: 3,5-bis-benzyloxy-pyridine-2-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-bis-benzyloxy-pyridine-2-carbonitrile(1000025-92-2)
• EPA Substance Registry System: 3,5-bis-benzyloxy-pyridine-2-carbonitrile(1000025-92-2)

Safety Data

• Hazardous Substances Data: 1000025-92-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3,5-bis-benzyloxy-pyridine-2-carbonitrile is used as a building block for the synthesis of diverse compounds with potential biological activity. Its versatile reactivity and functional groups allow for the development of new chemical reactions and synthetic methodologies.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3,5-bis-benzyloxy-pyridine-2-carbonitrile serves as a key intermediate in the preparation of pharmaceuticals. Its unique structure contributes to the creation of bioactive molecules that can be further optimized for therapeutic applications.
Used in Pharmaceutical Development:
3,5-bis-benzyloxy-pyridine-2-carbonitrile is utilized in the pharmaceutical industry as a precursor for the synthesis of various drugs. Its presence in the molecular structure can enhance the pharmacological properties of the final product, making it an essential component in drug discovery and development processes.

Upstream product

• 85331-33-5 2-Cyano-3,5-dichloropyridine 
• 100-51-6 benzyl alcohol 

Relevant articles and documents

COMPOUNDS HAVING HEPATIAL DISEASE EFFECTIVE

The invention discloses a compound with a hepatopathy curative effect, and the compound is a compound shown as a general formula (I), an optical isomer or pharmaceutically acceptable salt thereof, canbe applied to treatment or prevention of hepatopathy, particularly to drugs for treating or preventing fatty liver, liver fibrosis or liver cirrhosis, and has a good application prospect.

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products (i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation-incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of eFT226 (Zotatifin), a compound with excellent physicochemical properties and significant antitumor activity that supports clinical development.

EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Prolyl hydroxylase inhibitors and methods of use

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.